NEW YORK (GenomeWeb News) — Underwriters taking part in Rosetta Genomics’ initial public offering last month bought 562,000 additional shares as part of an over-allotment.
.
The over-allotment makes the total IPO’s net value $26.2 million on 4.3 million shares sold, after the initial sale of 3.75 million shares at $7 a share.
 
Rosetta’s stock was down 2.4 percent at $8.15 in early-afternoon trading today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.